CEL-SCI

CEL-SCI ROA

The Return on Assets (ROA) of CEL-SCI (CVM) as of Oct 29, 2026 is -90.25 %. In the previous year, Return on Assets (ROA) was -99.74 % — a change of -9.51% (higher).

ROA

-90.25 %

YoY

-9.51%

Last updated:

In 2025, CEL-SCI's return on assets (ROA) was -90.25 %, a -9.51% increase from the -99.74 % ROA in the previous year.

The CEL-SCI ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-107.61 USD
Jan 1, 2019
-89.39 USD
Jan 1, 2020
-74.69 USD
Jan 1, 2021
-47.93 USD
Jan 1, 2022
-72.64 USD
Jan 1, 2023
-106.02 USD
Jan 1, 2024
-99.74 USD
Jan 1, 2025
-90.25 USD
The CEL-SCI ROA history
YEARROAYoY
-90.25 %-9.51%
-99.74 %-5.93%
-106.02 %+45.95%
-72.64 %+51.57%
-47.93 %-35.83%
-74.69 %-16.45%
-89.39 %-16.93%
-107.61 %+71.74%
-62.66 %-36.62%
-98.86 %-55.96%
-224.47 %+57.73%
-142.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CEL-SCI Stock analysis

What does CEL-SCI do? CEL-SCI Corp develops immunotherapies targeting cancer and infectious diseases, focusing on Multikine for head and neck cancers and anal warts in HIV/HPV co-infected patients, and L.E.A.P.S. technology for influenza and rheumatoid arthritis treatments. The company generates revenue through research and development services, with products like LEAPS-H1N1-DC and CEL-2000/CEL-4000 in clinical development. Its primary customers are pharmaceutical partners and research institutions seeking novel therapeutic solutions. The firm operates within the biotechnology sector, emphasizing immune system activation for disease treatment. Multikine and L.E.A.P.S. therapies represent CEL-SCI's core product pipeline, with Multikine targeting head and neck cancers and cervical dysplasia, while L.E.A.P.S. focuses on pandemic influenza and rheumatoid arthritis. The company monetizes its R&D efforts by advancing these therapies through clinical trials, aiming for partnerships with larger pharmaceutical firms for commercialization. Its segment is defined by the development of investigational drugs and vaccines, with no current commercial products generating direct revenue. CEL-SCI's revenue model relies on securing funding for clinical trials and potential future licensing agreements. The company's focus on immune-based therapies for unmet medical needs attracts interest from biotech investors and collaborative partners. Its product candidates, including LEAPS-H1N1-DC and CEL-2000, are positioned for development into marketable treatments, though no sales have occurred yet. CEL-SCI is one of the most popular companies on Eulerpool.

ROA Details

Understanding CEL-SCI's Return on Assets (ROA)

CEL-SCI's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing CEL-SCI's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider CEL-SCI's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in CEL-SCI’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about CEL-SCI stock

Return on Assets (ROA) of CEL-SCI is -90.25 % in 2025.

Return on Assets (ROA) of CEL-SCI changed from -99.74 % to -90.25 %, representing a -9.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) CEL-SCI since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s CEL-SCI with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CEL-SCI

All Key Metrics — CEL-SCI